Note 13 - Segment Information

6 Months Ended

Oct. 31, 2014

Note 13 - Segment Information:

Note 13 - Segment Information

NOTE 13 - SEGMENT INFORMATION

The following information is presented in accordance with ASC Topic 280, “Segment Reporting”, for the three months ended October 31, 2014 and 2013; we operated in three reportable business segments - (1) natural sweetener (stevioside), (2) traditional Chinese medicines and (3) corporate and other. Our reportable segments are strategic business units that offer different products and are managed separately based on the fundamental differences in their operations. Condensed financial information with respect to these reportable business segments for the three and six months ended October 31, 2014 and 2013 is as follows:

	Three Months Ended October 31,		Six Months Ended October 31,
	2014	2013	2014	2013
Revenues:
Chinese medicine – third party	$         576,868	$         577,262	$      1,099,061	$      1,148,822
Chinese medicine – related party	0	0	0	0
Total Chinese medicine	576,868	577,262	1,099,061	1,148,822
Stevioside – third party	2,396,023	1,656,015	4,824,731	2,658,050
Stevioside – related party	1,054,439	590,680	1,940,047	1,733,991
Total Stevioside	3,450,462	2,246,695	6,764,778	4,392,041
Total segment and consolidated revenues	$      4,027,330	$      2,823,957	$      7,863,839	$      5,540,863
Interest (expense) income:
Chinese medicine	$                 (14)	$                134	$                   126	$                278
Stevioside	(64,352)	(17,996)	(127,446)	(33,528)
Total segment and consolidated interest expense	$         (64,366)	$         (17,862)	$         (127,320)	$         (33,250)
Depreciation and amortization:
Chinese medicine	$            20,383	$           23,557	$               39,372	$           46,033
Stevioside	446,138	519,051	1,133,561	1,042,240
Total segment and consolidated depreciation and amortization	$         466,521	$         542,608	$         1,172,933	$     1,088,273
Income (loss) before income taxes:
Chinese medicine	$           33,361	$        (42,142)	$              57,477	$         (51,000)
Stevioside	(247,850)	(843,764)	(679,457)	(1,467,270)
Corporate and other	(17,030)	(71,930)	(86,211)	(24,940)
Total consolidated (loss) income before income taxes	$       (231,519)	$      (957,836)	$          (708,191)	$   (1,543,210)

	October 31, 2014	April 30, 2014
Segment tangible assets:
Chinese medicine	$       647,545	$       605,918
Stevioside	13,938,733	14,332,440
Corporate and other	0	0
Total consolidated assets	$ 14,586,278	$ 14,938,358